Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNAPURNA: Combination DAA Therapy for HCV Genotype 1
NCT01628094Phase 2Completed
- Sponsor
- Roche
- Start
- Jun 2012
- Primary completion
- Nov 2013
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of setrobuvir, danoprevir and mericitabine in hepatitis C (HCV) (6 arms), sponsored by Roche. Primary endpoints: Sustained Virological Response 12 weeks after end of treatment and Incidence of Adverse Events. Started Jun 2012; status: completed.
02
Drugs
setrobuvirdanoprevirmericitabine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01628094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01628094.